Physician profile

Danielle Jackson

Emergency Medicine · West Reading, PA

NPI 1447982012

$690.34

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$553.33
Education$137.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $209.51 2023-2024
Janssen Pharmaceuticals, INC $147.59 2024 Xarelto
Medical Device Business Services, INC. $137.01 2024
Fisher & Paykel Healthcare INC $107.80 2023-2024 Fisher & Paykel Healthcare
Ethicon US, LLC $49.93 2024 Dermabond
Alexion Pharmaceuticals, INC. $24.32 2023 Soliris
Pfizer INC. $14.18 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Danielle Jackson

$690.34

in general payments reported 2019-2025

Years
2023-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/11325554/danielle-jackson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.